Updates in the Management of Cephalosporin-Resistant Gram-Negative Bacteria

Overview

Journal Curr Infect Dis Rep

Specialty Infectious Diseases

Date 2016 Oct 16

PMID 27743202

Citations 5

Authors

Andre Arizpe

Kelly R Reveles

Shrina D Patel

Samuel L Aitken

Affiliations

Soon will be listed here.

Abstract

Resistance to cephalosporins is now common among Gram-negative bacterial infections, including those caused by the Enterobacteriaceae and Pseudomonas aeruginosa, posing a major threat to public health. As resistance to the traditional drugs of choice for these infections, carbapenems, has also become increasingly common, interest in cefepime and piperacillin-tazobactam as carbapenem-sparing alternatives has increased. Additionally, the availability of the novel β-lactam-β-lactamase inhibitor combinations ceftolozane-tazobactam and ceftazidime-avibactam has added to the antimicrobial armamentarium available to treat these multidrug-resistant infections. Here, we review the recent literature on the use of carbapenem-sparing alternatives and highlight the potential utility of novel antimicrobials.

Citing Articles

Clinical Characteristics and Optimization of Empirical Antimicrobial Therapy for Febrile Neutropenia in Patients With Hematologic Malignancies.

Cui Y, Liu X, Feng S Infect Drug Resist. 2025; 18:715-729.

PMID: 39936036 PMC: 11812456. DOI: 10.2147/IDR.S493670.

Emergence of - and (A)-Producing Isolated from Hospital Sewage.

Mo H, Lin X, Liu M, Liang H Infect Drug Resist. 2022; 15:3173-3177.

PMID: 35754787 PMC: 9215840. DOI: 10.2147/IDR.S363019.

Carbapenem versus Cefepime or Piperacillin-Tazobactam for Empiric Treatment of Bacteremia Due to Extended-Spectrum-β-Lactamase-Producing in Patients with Hematologic Malignancy.

Benanti G, Brown A, Shigle T, Tarrand J, Bhatti M, McDaneld P Antimicrob Agents Chemother. 2018; 63(2).

PMID: 30509935 PMC: 6355563. DOI: 10.1128/AAC.01813-18.

Ecological effects of cefepime use during antibiotic cycling on the Gram-negative enteric flora of ICU patients.

Venturini C, Ginn A, Wilson B, Tsafnat G, Paulsen I, Partridge S Intensive Care Med Exp. 2018; 6(1):19.

PMID: 30054764 PMC: 6063807. DOI: 10.1186/s40635-018-0185-2.

Ceftazidime-Avibactam: A Review in the Treatment of Serious Gram-Negative Bacterial Infections.

Shirley M Drugs. 2018; 78(6):675-692.

PMID: 29671219 DOI: 10.1007/s40265-018-0902-x.

References

Zanetti G, Bally F, Greub G, Garbino J, Kinge T, Lew D . Cefepime versus imipenem-cilastatin for treatment of nosocomial pneumonia in intensive care unit patients: a multicenter, evaluator-blind, prospective, randomized study. Antimicrob Agents Chemother. 2003; 47(11):3442-7. PMC: 253800. DOI: 10.1128/AAC.47.11.3442-3447.2003. View

Jacoby G . AmpC beta-lactamases. Clin Microbiol Rev. 2009; 22(1):161-82, Table of Contents. PMC: 2620637. DOI: 10.1128/CMR.00036-08. View

Jacobs D, DiTursi S, Ruh C, Sharma R, Claus J, Banjade R . Combination treatment with extended-infusion ceftazidime/avibactam for a KPC-3-producing Klebsiella pneumoniae bacteraemia in a kidney and pancreas transplant patient. Int J Antimicrob Agents. 2016; 48(2):225-7. DOI: 10.1016/j.ijantimicag.2016.06.002. View

Wu G, Abraham T, Lee S . Ceftazidime-Avibactam for Treatment of Carbapenem-Resistant Enterobacteriaceae Bacteremia. Clin Infect Dis. 2016; 63(8):1147-8. DOI: 10.1093/cid/ciw491. View

Vickery S, McClain D, Wargo K . Successful Use of Ceftolozane-Tazobactam to Treat a Pulmonary Exacerbation of Cystic Fibrosis Caused by Multidrug-Resistant Pseudomonas aeruginosa. Pharmacotherapy. 2016; 36(10):e154-e159. DOI: 10.1002/phar.1825. View

Patel U, Nicolau D, Sabzwari R . Successful Treatment of Multi-Drug Resistant Pseudomonas aeruginosa Bacteremia with the Recommended Renally Adjusted Ceftolozane/Tazobactam Regimen. Infect Dis Ther. 2016; 5(1):73-9. PMC: 4811840. DOI: 10.1007/s40121-016-0104-3. View

Harris P, Tambyah P, Paterson D . β-lactam and β-lactamase inhibitor combinations in the treatment of extended-spectrum β-lactamase producing Enterobacteriaceae: time for a reappraisal in the era of few antibiotic options?. Lancet Infect Dis. 2015; 15(4):475-85. DOI: 10.1016/S1473-3099(14)70950-8. View

Denisuik A, Lagace-Wiens P, Pitout J, Mulvey M, Simner P, Tailor F . Molecular epidemiology of extended-spectrum β-lactamase-, AmpC β-lactamase- and carbapenemase-producing Escherichia coli and Klebsiella pneumoniae isolated from Canadian hospitals over a 5 year period: CANWARD 2007-11. J Antimicrob Chemother. 2013; 68 Suppl 1:i57-65. DOI: 10.1093/jac/dkt027. View

Kuti J, Ghazi I, Quintiliani Jr R, Shore E, Nicolau D . Treatment of multidrug-resistant Pseudomonas aeruginosa with ceftolozane/tazobactam in a critically ill patient receiving continuous venovenous haemodiafiltration. Int J Antimicrob Agents. 2016; 48(3):342-3. DOI: 10.1016/j.ijantimicag.2016.06.005. View

10.

Jang W, Park Y, Park K, Yu J . Evaluation of MicroScan WalkAway and Vitek 2 for determination of the susceptibility of extended-spectrum β-lactamase-producing Escherichia coli and Klebsiella pneumoniae isolates to cefepime, cefotaxime and ceftazidime. J Antimicrob Chemother. 2013; 68(10):2282-5. DOI: 10.1093/jac/dkt172. View

11.

Fisher J, Mobashery S . The sentinel role of peptidoglycan recycling in the β-lactam resistance of the Gram-negative Enterobacteriaceae and Pseudomonas aeruginosa. Bioorg Chem. 2014; 56:41-8. PMC: 4161644. DOI: 10.1016/j.bioorg.2014.05.011. View

12.

Lopez-Cerero L, Picon E, Morillo C, Hernandez J, Docobo F, Pachon J . Comparative assessment of inoculum effects on the antimicrobial activity of amoxycillin-clavulanate and piperacillin-tazobactam with extended-spectrum beta-lactamase-producing and extended-spectrum beta-lactamase-non-producing Escherichia coli.... Clin Microbiol Infect. 2009; 16(2):132-6. DOI: 10.1111/j.1469-0691.2009.02893.x. View

13.

Retamar P, Lopez-Cerero L, Muniain M, Pascual A, Rodriguez-Bano J . Impact of the MIC of piperacillin-tazobactam on the outcome of patients with bacteremia due to extended-spectrum-β-lactamase-producing Escherichia coli. Antimicrob Agents Chemother. 2013; 57(7):3402-4. PMC: 3697383. DOI: 10.1128/AAC.00135-13. View

14.

Lee N, Lee C, Huang W, Tsui K, Hsueh P, Ko W . Cefepime therapy for monomicrobial bacteremia caused by cefepime-susceptible extended-spectrum beta-lactamase-producing Enterobacteriaceae: MIC matters. Clin Infect Dis. 2012; 56(4):488-95. DOI: 10.1093/cid/cis916. View

15.

Lister P, Wolter D, Hanson N . Antibacterial-resistant Pseudomonas aeruginosa: clinical impact and complex regulation of chromosomally encoded resistance mechanisms. Clin Microbiol Rev. 2009; 22(4):582-610. PMC: 2772362. DOI: 10.1128/CMR.00040-09. View

16.

Magill S, Edwards J, Bamberg W, Beldavs Z, Dumyati G, Kainer M . Multistate point-prevalence survey of health care-associated infections. N Engl J Med. 2014; 370(13):1198-208. PMC: 4648343. DOI: 10.1056/NEJMoa1306801. View

17.

Kang C, Cha M, Kim S, Wi Y, Chung D, Peck K . Extended-spectrum cephalosporins and the inoculum effect in tests with CTX-M-type extended-spectrum β-lactamase-producing Escherichia coli: potential clinical implications of the revised CLSI interpretive criteria. Int J Antimicrob Agents. 2014; 43(5):456-9. DOI: 10.1016/j.ijantimicag.2014.01.030. View

18.

Falagas M, Tansarli G, Rafailidis P, Kapaskelis A, Vardakas K . Impact of antibiotic MIC on infection outcome in patients with susceptible Gram-negative bacteria: a systematic review and meta-analysis. Antimicrob Agents Chemother. 2012; 56(8):4214-22. PMC: 3421594. DOI: 10.1128/AAC.00663-12. View

19.

Bulik C, Tessier P, Keel R, Sutherland C, Nicolau D . In vivo comparison of CXA-101 (FR264205) with and without tazobactam versus piperacillin-tazobactam using human simulated exposures against phenotypically diverse gram-negative organisms. Antimicrob Agents Chemother. 2011; 56(1):544-9. PMC: 3256089. DOI: 10.1128/AAC.01752-10. View

20.

Tsai H, Chen Y, Tang H, Huang C, Liao C, Chu F . Carbapenems and piperacillin/tazobactam for the treatment of bacteremia caused by extended-spectrum β-lactamase-producing Proteus mirabilis. Diagn Microbiol Infect Dis. 2014; 80(3):222-6. DOI: 10.1016/j.diagmicrobio.2014.07.006. View